Therapies Targeting Stroke Recovery. Issue 1 (7th December 2022)

• Record Type: Journal Article
• Authors: Richards, Lorie G.; Cramer, Steven C.
• Is Part Of: Stroke. Volume 54:Issue 1(2023)
• Page Start: 265
• Page End: 269
• Publication Date: 2022-12-07
• Subjects: clinical trial -- depression -- phenotype -- precision medicine -- rehabilitation -- stroke -- therapeutics; Cerebrovascular disease -- Periodicals; Cerebral circulation -- Periodicals; 616.81
• DOI: 10.1161/STROKEAHA.122.041729
• Languages: English
• ISSNs: 0039-2499

Abstract

Abstract: Stroke recovery therapeutics include many classes of intervention and numerous treatment targets. Stroke is a very heterogeneous disease. As such, stroke recovery therapeutics benefit from a personalized medicine approach that considers intersubject differences, such as in infarct location or stroke severity, when assigning treatment. Prediction of treatment responders can be improved by incorporating biological measures, such as neural injury and neural function, as the bedside behavioral phenotype has an incomplete relationship with the biological events underlying stroke recovery. Another ramification of high variability between patients is the need to examine effects of restorative therapies in relation to dose, time poststroke, and stroke severity in clinical trials. For example, enrollment across a wide time interval poststroke or in a population with a very broad range of deficits means high variance across patients in the biological state of the brain. The doses of rehabilitation therapy being studied are often low; it takes substantial practice to acquire a skill in the healthy brain; this is more, not less, pronounced after a stroke. Recognition and treatment of poststroke depression represents a major unmet need. These points are considered in the context of a review of recent advances in stroke recovery therapeutics.